The effect of Empagliflozin on outcomes of patients with myocardial infarction undergoing primary PCI
Phase 3
Recruiting
- Conditions
- ST Elevation myocardial infarction.ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
- Registration Number
- IRCT20220809055645N7
- Lead Sponsor
- Rasht University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Patients with ST segment elevation myocardial infarction (STEMI) undergoing successful Primary PCI without complications
Based on New York Heart Association (NYHA) functional class I,II,III
Informed consent for participation in study
Exclusion Criteria
Failure of primary PCI
Empagliflozin contraindications
Valvular heart disease with moderate and higher severity
Patients who need hemodynamic support during hospitalization
Not willing to continue participation in study
Receiving drugs ,eg Non-steroidal anti-inflammatory drugs (NSAIDs) which can not be denied
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Myocardial reinfarction. Timepoint: During 40-day follow up. Method of measurement: According to symptoms and ECG findings.;Stroke. Timepoint: During 40-day follow up. Method of measurement: According to symptoms and physical examinations.;Cardiac mortality. Timepoint: During 40-day follow up. Method of measurement: Cardiac death according to AHA guideline determined as paroxysmal cardiac arrest with no respiratory and circulatory response.
- Secondary Outcome Measures
Name Time Method Ejection fraction. Timepoint: During 40-day follow up. Method of measurement: By echocardiography.;Systolic heart failure. Timepoint: During 40-day follow up. Method of measurement: By echocardiography.;Re admission. Timepoint: During 40-day follow up. Method of measurement: Documented records.;Angina. Timepoint: During 40-day follow up. Method of measurement: History.;Second revascularization. Timepoint: During 40-day follow up. Method of measurement: Based on symptoms ECG and echocardiographic findings.;Empagliflozin complications. Timepoint: During 40-day follow up. Method of measurement: Based on history, symptoms and echocardiography findings.